Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of chronic myeloid leukemia in chronic phase (CML-CP) associated with BCR-ABL1 quantifiable by RQ-PCR (IS)~* No other current or planned anti-leukemia therapies excluding hydroxyurea treatment for up to two months.~* ECOG Performance status 0,1, or 2~* Adequate organ function as defined by: Total bilirubin \< 1.5 x ULN (ULN = upper limit of normal in a local institution lab) in absence of Gilbert genotype; ASAT and ALAT \< 2.5 x ULN. Creatinine \< 2x ULN. Potassium, magnesium and phosphate not below LLN (LLN= lower level of normal)~* Life expectancy of more than 12 months in the absence of any intervention~* Patient has given written informed consent to participate in the study~Exclusion Criteria:~* Prior accelerated phase or blast crisis~* Uncontrolled or significant cardiovascular disease, including any of the following:~  * A myocardial infarction within 6 months~ * Uncontrolled angina within 3 months~ * Congestive heart failure within 3 months~ * Diagnosed or suspected congenital long QT syndrome~ * Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de Pointe)~ * Prolonged QTcF interval \> 450 msec on pre-entry ECG~* Atypical BCR-ABL1 transcript not quantifiable by RQ-PCR.~* Another primary malignant disease, which requires systemic treatment (chemotherapy or radiation) Severe and/or life-threatening medical disease including acute liver disease~* History of significant congenital or acquired bleeding disorder unrelated to cancer~* Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of dasatinib~* Patients actively receiving therapy with strong CYP3A4 inhibitors and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug~* Patients who are currently receiving treatment with any medications that have the potential to prolong the QT interval and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug~* Female patients who are: pregnant, breast feeding or potentially fertile without a negative pregnancy test prior to baseline or unwilling to use contraception on trial~* Previous history of pericarditis or pleuritis~* History of non-compliance, abuse of alcohol, illicit drugs, severe psychiatric disorders or other inability to grant informed consent.~* Current treatment for depression.~* Hypersensitivity to any interferon preparation;~* Autoimmune hepatitis or a history of autoimmune disease;~* Pre-existing thyroid disease unless it can be controlled with conventional treatment;~* Epilepsy and/or compromised central nervous system (CNS) function;~* HCV/HIV patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Dasatinib + PegIFN (Type: EXPERIMENTAL): Dasatinib 100mg OD for three months single drug, with subsequent addition of PegIFN 15 μg/ week for 3 months. If well tolerated (less than grade 2 non-hematological or grade 3 hematological AE) the dose should be increased to 25μg weekly for the remaining 9 months on combination treatment. Thereafter dasatinib will be given as monotherapy. Patients will be followed for 24 months totally.

Based on this trial design, predict the completion outcome and termination type (if applicable).